AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Veery Capital LLC

Veery Capital LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 4.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,503 shares of the company’s stock after purchasing an additional 157 shares during the quarter. Veery Capital LLC’s holdings in AstraZeneca were worth $230,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $28,000. Groupama Asset Managment boosted its holdings in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after buying an additional 101,225 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of AstraZeneca in the 3rd quarter valued at $45,000. Finally, Versant Capital Management Inc raised its stake in AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after acquiring an additional 707 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AZN has been the topic of several research reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $66.60 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a 50-day simple moving average of $66.11 and a 200-day simple moving average of $74.49. The company has a market capitalization of $206.50 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.87 EPS. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.